Cabergoline Improves Metabolic Status in Hyperprolactinemia - Medscape

A single-center, observational study suggests that 6 months of treatment with the dopamine agonist cabergoline improves cardiometabolic measures in patients with a prolactinoma and hyperprolactinemia.

Researchers published the study covered in this summary on medRxiv.org as a preprint that has not yet been peer reviewed.